Investigation of the pathogenesis of type 1 and insulin-dependent diabetes mellitus using a noninvasive pancreatic beta cell imaging technique

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1051220023

Enrollment

Registered

2022-05-11

Start date

2022-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus Type 1 diabetes mellitus

Interventions

PET scanning for patients of Type 1 Diabetes Mellitus. Test drug: [18F]-FB(ePEG12)12-Ex4 Dosage: 37-74 MBq, increase or decrease based on body weight and probe yield. The amount of exenatide should be

D049268

Positron-Emission Tomography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Clinically diagnosed with type 1 diabetes mellitus or recognized as insulin-dependent diabetes mellitus 2) Aged 20 years or older at the time of the informed consent 3) Written consent has been obtained from the subject for participation in this study

Exclusion criteria

Exclusion criteria: 1) Patients have severe liver or kidney dysfunction 2) Inability to discontinue GLP-1 related products 3) Patients who are unsuitable or contraindicated for exenatide administration 4) Patients with alcohol intolerance 5) Patients who were judged to be inappropriate for enrolment by the physician

Design outcomes

Primary

Measure	Time frame
Pathophysiological analysis of type 1 diabetes mellitus by evaluating the relationship between the amount of pancreatic beta cells obtained by PET imaging and existing clinical indices.	—

Contacts

Public ContactHIROYUKI FUJIMOTO

Kyoto university

fujimo57@kuhp.kyoto-u.ac.jp+81-757513560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026